Avacta announces clinical study of AVA6000
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Read More
Tag: clinical study
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
